Track record · closed signal

AbbVie Inc. (ABBV) — closed signal from October 20, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 18, 2026 — -7.5% at the close.

Predicted vs. what happened

ABBV price · publication thesis → realized outcomesplit-adjusted

$228.00 – $233.00Entry zone — fair-value band

$231.75Published — price the day we called it

$254.93Target — the price the thesis aimed for

$239.29Peak — highest point inside the window, not a realized return

$214.35Window close — end-of-window price, context only

What happened

Partial

Reached 33% of the predicted growth at its peak, without hitting the target.

At window close

-7.5%

realized, from the publication price to the last close inside the window

Peak gain

+3.3%

peak, from the publication price — not a realized return

S&P 500, same window

+3.3%

SPY over the identical days, dividend-adjusted

Window close

$214.35

last close inside the window, ended January 18, 2026

Peak price

$239.29

peak on November 13, 2025 — not a realized return

Days to target

—

The thesis — published October 20, 2025

Predicted growth

+10%

over the measurement window

Target price

$254.93

the price the thesis aimed for

Entry zone

$228.00 – $233.00

the fair-value band we waited for

Price at publication

$231.75

published October 20, 2025

Confidence

65%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

AbbVie looks like it dropped more than usual and could bounce over the next 1-3 months. Fresh news that it bought rights to a new psychiatry drug lifts the mood after several down days. The company generates steady, defensive cash, which can help steady the stock. Signs of a turn are not fully in place yet, so the rebound case improves if price and trading interest begin to firm up from here.

Primary drivers

New psychiatry drug deal strengthens pipeline and may lift future sales
Stock fell too far too fast and may move back toward a more typical range
Investor mood is positive, which can draw more interest to the shares
Strong, predictable cash flow helps during uncertain market conditions

How it played out

ABBV: thesis missed the target

Lyra published ABBV at $231.75 on 2025-10-20 with expected growth of 10%. The thesis pointed to a psychiatry drug deal, a stock that had fallen too far too fast, positive investor mood, and steady defensive cash flow. It was a rebound case over the short-term window.

Inside the window, ABBV peaked at $239.29 on 2025-11-13, a 3.3% gain. It stayed below the $254.93 target and never reached it. By 2026-01-18, it ended at $214.35. The thesis only partly played out early, then missed.

What happened during the window

On 2025-10-31, AbbVie reported third-quarter 2025 results, including $15.78 billion in revenue and adjusted earnings of $1.86 per share. On 2026-01-13, The Wall Street Journal reported that AbbVie had reached a deal with the Trump administration involving a $100 billion U.S. investment plan and lower Medicaid prices.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABBV signals